Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more
Evotec SE (EVOTF) - Total Assets
Latest total assets as of September 2025: $1.77 Billion USD
Based on the latest financial reports, Evotec SE (EVOTF) holds total assets worth $1.77 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Evotec SE - Total Assets Trend (2001–2024)
This chart illustrates how Evotec SE’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Evotec SE - Asset Composition Analysis
Current Asset Composition (December 2024)
Evotec SE's total assets of $1.77 Billion consist of 35.7% current assets and 64.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.0% |
| Accounts Receivable | $218.38 Million | 11.4% |
| Inventory | $31.12 Million | 1.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $26.44 Million | 1.4% |
| Goodwill | $282.85 Million | 14.8% |
Asset Composition Trend (2001–2024)
This chart illustrates how Evotec SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evotec SE's current assets represent 35.7% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 16.0% of total assets in 2024, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 14.8% of total assets.
Evotec SE Competitors by Total Assets
Key competitors of Evotec SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Evotec SE - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Evotec SE generates 0.42x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Evotec SE is currently not profitable relative to its asset base.
Evotec SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.12 | 2.09 | 3.16 |
| Quick Ratio | 2.03 | 1.99 | 3.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $418.65 Million | $ 364.48 Million | $ 450.38 Million |
Evotec SE - Advanced Valuation Insights
This section examines the relationship between Evotec SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | -16.8% |
| Total Assets | $1.91 Billion |
| Market Capitalization | $1.12 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Evotec SE's assets below their book value (0.59 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Evotec SE's assets decreased by 16.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Evotec SE (2001–2024)
The table below shows the annual total assets of Evotec SE from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.91 Billion | -16.81% |
| 2023-12-31 | $2.30 Billion | +1.85% |
| 2022-12-31 | $2.26 Billion | +0.99% |
| 2021-12-31 | $2.24 Billion | +52.79% |
| 2020-12-31 | $1.46 Billion | +23.88% |
| 2019-12-31 | $1.18 Billion | +52.99% |
| 2018-12-31 | $771.88 Million | +15.68% |
| 2017-12-31 | $667.27 Million | +89.91% |
| 2016-12-31 | $351.37 Million | +21.77% |
| 2015-12-31 | $288.54 Million | +28.47% |
| 2014-12-31 | $224.60 Million | -1.22% |
| 2013-12-31 | $227.38 Million | +0.87% |
| 2012-12-31 | $225.43 Million | +3.31% |
| 2011-12-31 | $218.21 Million | +13.74% |
| 2010-12-31 | $191.86 Million | +30.87% |
| 2009-12-31 | $146.60 Million | -19.85% |
| 2008-12-31 | $182.90 Million | -12.02% |
| 2007-12-31 | $207.88 Million | +1.14% |
| 2006-12-31 | $205.53 Million | +10.43% |
| 2005-12-31 | $186.11 Million | +162.46% |
| 2004-12-31 | $70.91 Million | +69.94% |
| 2003-12-31 | $41.73 Million | +123.10% |
| 2002-12-31 | $18.70 Million | -48.34% |
| 2001-12-31 | $36.20 Million | -- |